+Vote!
Asiaing.com (Free subscription) | 08/16/2008
GENZYME is one of the world's leading biotechnology companies, dedicated to making a powerful difference in the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe. Genzyme today provides innovative therapies to patients in more than 90 countries.
1Vote!
Red Orbit (Free subscription) | 08/12/2008
By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation.
1Vote!
Red Orbit (Free subscription) | 08/07/2008
Genzyme and Isis Pharmaceuticals have initiated a Phase III study of mipomersen in patients with heterozygous familial hypercholesterolemia, a genetic disorder that causes exceptionally high levels of low-density lipoprotein cholesterol.
+Vote!
Medical News Today (Free subscription) | 08/07/2008
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol. It is the first of four new trials the companies plan to initiate by the end of this year, and the second late-stage study...
+Vote!
Red Orbit (Free subscription) | 08/06/2008
Biotechnology Company Experiences 30 Percent Increase in Efficiency by Mobilizing Enterprise Applications Vaultus Mobile Technologies Oonagh O'Regan, 617-399-1105 ooregan@vaultus.com or Schwartz Communications Chuck Tanowitz, 781-684-0770 or Joe Palladino, 781-684-0770 vaultus@schwartz-pr.com Logo: http://www.vaultus.com When Genzyme's European field representatives visit their clients, they will now...
+Vote!
Business Wire (Free subscription) | 08/05/2008
BOSTON--(BUSINESS WIRE)--When Genzyme’s European field representatives visit their clients, they will now have the latest client and sales information from
+Vote!
Nature (Free subscription) | 08/01/2008
Head of R&D, Genzyme Europe.Co-chairman of the European Management Committee, Member of the Corporate Portfolio Management Committee and Head of R&D for Genzyme Europe, Carlo Incerti is responsible for the strategic direction of Genzyme R&D. President of the Board of European Biopharmaceutical Enterprises since
+Vote!
Antitrust & Competition Policy Blog (Free subscription) | 07/30/2008
Posted by D. Daniel Sokol Richard Gilbert (University of California at Berkeley - Economics) offers his thoughts on Innovation Markets after Genzyme/Novazyme. ABSTRACT: The U.S. Federal Trade Commission alleged adverse effects on innovation in about forty percent of all merger...
+Vote!
The Street (Free subscription) | 07/23/2008
The biotech beats adjusted profit targets by a penny a share, but it does not raise adjusted outlook.
+Vote!
Contract Pharma Breaking News (Free subscription) | 07/23/2008
Genzyme 2Q Revenues: $1.2 billion (+25%) 2Q Earnings: $69.6 million (-17%) YTD Revenues: $2.3 billion (+25%) YTD Earnings: $214.8 million (-11%) Comments: Myozyme sales were up 65% in the quarter to $77.2 million. The company is still awaiting approval of its Myozyme 2000L-scale facility in the U.S.; the FDA is expected to discuss the BLA in October. Cerezyme sales were up 13% to $319.4 million. Sales...
+Vote!
Business Spectator (Free subscription) | 07/23/2008
Revenue jumps 25 per cent on strong demand for genetic disorder medicines. 23 Jul 2008 11:40 PM
+Vote!
The Boston Business Journal (Free subscription) | 07/23/2008
Genzyme Corp. enjoyed continued revenue growth during its fiscal 2008 second quarter, but net income dipped due to licensing fees for a new cholesterol drug under development.
2Vote!
sunilnair | 12/24/2007
Genzyme Corporation: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually...
